Information Provided By:
Fly News Breaks for December 23, 2019
Dec 23, 2019 | 10:34 EDT
After Karyopharm announced this morning that it submitted an NDA to the FDA for accelerated approval for Xpovio in patients with relapsed or refractory diffuse large B-Cell lymphoma, H.C. Wainwright analyst Edward White said he expects Xpovio could receive approval and sees a launch in 2021, adding that he estimates sales of $241.2M in 2026 for the DLBCL indication. White keeps a Buy rating and $36 price target on Karyopharm shares.